BiotechTube

OMS302 + Phenylephrine HCl

Phase 3Completed
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Unilateral Cataract Extraction

Conditions

Unilateral Cataract Extraction, Congenital Cataract

Trial Timeline

Jul 1, 2014 → Sep 12, 2016

NCT ID
NCT02132312

About OMS302 + Phenylephrine HCl

OMS302 + Phenylephrine HCl is a phase 3 stage product being developed by Omeros Corporation for Unilateral Cataract Extraction. The current trial status is completed. This product is registered under clinical trial identifier NCT02132312. Target conditions include Unilateral Cataract Extraction, Congenital Cataract.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02132312Phase 3Completed

Competing Products

2 competing products in Unilateral Cataract Extraction

See all competitors
ProductCompanyStageHype Score
CGF166NovartisPhase 1/2
41
SENS-111 100mg + SENS-111 200mg + Placebo Oral TabletSensorionPhase 2
44

Other Products from Omeros Corporation

1% preservative-free lidocaine + Phenylephrine 1.0%/ Ketorolac 0.3%Approved
80
OmidriaApproved
80
OMS302 + PlaceboPhase 3
72
Part 1 OMS302 + Part 2 OMS302 + Part 2 PlaceboPhase 3
72
OMS103HP + VehiclePhase 3
72